Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Kobayashi T, Kuroda J, Fuchida S, Kaneko H, Yagi H, Shibayama H, Tanaka H, Kosugi S, Uoshima N, Kobayashi M, Adachi Y, Ohta K, Ishii K, Uchiyama H, Matsuda M, Nakatani E, Tsudo M, Shimazaki C, Takaori-Kondo A, Nomura S, Matsumura I, Taniwaki M, Kanakura Y; KMF investigators.
Kobayashi T, et al. Among authors: uchiyama h.
Int J Hematol. 2015 Jan;101(1):37-45. doi: 10.1007/s12185-014-1696-6. Epub 2014 Nov 11.
Int J Hematol. 2015.
PMID: 25385278